We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hvivo Plc | HVO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.10 | 6.15% | 19.00 | 16:35:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.25 | 18.25 | 19.15 | 19.00 | 17.90 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 09/04/2024 | Final | GBP | 0.002 | 18/04/2024 | 19/04/2024 | 20/05/2024 |
| 25/04/2023 | Special | GBP | 0.0045 | 04/05/2023 | 05/05/2023 | 09/06/2023 |
| Top Posts |
|---|
Posted at 13/1/2025 08:20 by troutisout So about 6 months behind the timeline, I wonder if the client is still onboard? There has been a lot of news about hMPV recently..."28/06/2023 7:00am UK Regulatory Hvivo (LSE:HVO) RNS Number : 1072E hVIVO PLC 28 June 2023 hVIVO plc ("hVIVO" or the "Company") hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation and world leader in testing infectious and respiratory disease products using human challenge clinical trials, is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate. hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in H1 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from H2 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024. The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide(1) . Up to 16% of the children infected with hMPV develop more severe symptoms(2) , with over 16,000 deaths worldwide in children under the age of five each year.(3) Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.(4) Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "We are delighted to be developing the industry's first commercial hMPV human challenge model. The continued expansion of our challenge model portfolio aligns with our mission to deliver today's healthcare by empowering tomorrow's innovation. We hope to help our client to bring their treatment to patients faster through the utilisation of a new unique human challenge model. We will continue to expand our library of challenge models and provide a mechanism for our customers to expedite their drug development." Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "hVIVO's unique expertise and world leading capabilities enables us to provide our clients with a full human challenge service offering, including the development of bespoke challenge models. As demonstrated with RSV, hVIVO can also play a vital role in speeding up drug development for hMPV, which currently has no approved vaccine or antiviral treatment." |
Posted at 07/1/2025 17:09 by sikhthetech IIs buy using other people's money.It was 1gw and his mates talking about II holdings. sikhthetech - 07 Aug 2024 - 11:34:19 - 7823 of 9142 hVIVO plc - HVO Aishah "Neil Hermon has bought a small stake in clinical trials group Hvivo" " makes up 0.1% of the £637m Henderson Smaller Companies Trust (HSL) portfolio." "Hermon said in recent interim results that Hvivo offered a relatively cheap and effective way to undertake accelerated drug development." Yes, small stake. How much? 0.1% of £637m is £637k, yes k. Tiny, hardly significant. How's it compare to the sitting chairman dumped his near 50m holding, worth around £10m!!! It backs up what I've been saying, does it? IIs take tiny stakes as punts. sikhthetech - 08 Mar 2024 - 15:00:26 - 6946 of 7823 hVIVO plc - HVO pierre, "It's now a serious investable company imv" Such a serious investable company that the Chairman and founder dumped majority of his holding. ;-) How do the 1-2% holdings(punts) by institutions compare to the > 7m options held by the CEO? Not forgetting there's evidence, from company's own figures, showing growth has slowed significantly. Adding to the questionable business model. |
Posted at 10/12/2024 09:09 by troutisout I think there will be more contracts signed shortly and it isn't as if they will have to raise due to any slack in revenues for next year. This year has been a bumper year as they were able to pull more work through in H1 when they had all the facilities working together. Just like this one, the contracts signed last December and in January this year have revenues to be recognised over more than one year (both of them show revenues into 2025). I just wonder if they sign a couple more contracts soon, that they can recognise a lot of the revenue in 2025, volunteer recruitment is a huge part of the contract and that has to happen before a trial can take place, so don't get too heavily into a trial starting late in the year, a lot of work is done before the trial.When they mentioned looking for an acquisition, I looked at likely targets and found one in N. Ireland that looked bombed out, however that is now starting a decent re-rate and so not sure it will be a target for HVO now, but happy to have jumped aboard for another CRO's ride. There seems to be an upturn in CRO business after a lean period (HVO didn't suffer that lean period), some will point to RFK, but miss that a lot of HVO's challenge studies are for anti-virals and with no appetite for vaccine development, then you need something to treat the disease. Secondly these vaccines in development may take several years to get approved anyway so it would be silly for big pharma to stop development because of one politician. Good News today and expect more of it soon... |
Posted at 08/12/2024 20:20 by sikhthetech M5"I did not pay attention to you" "When CF sold part of his holding that was me out" The posts say otherwise. You sold a day after CF sold majority of his holding and I posted. As I said you wouldn't admit it. sikhthetech - 14 Feb 2024 - 13:49:19 - 6589 of 8843 hVIVO plc - HVO There you go, as predicted, this was repeatedly talked up. CF selling significant number, as he is now in profit. Why would he sell if there was significant growth ahead. sikhthetech - 04 Feb 2024 - 21:49:25 - 6386 of 6586 Whenever there's huge options awarded to 1 director then I see it as a red flag. A similar happened at RTHM, which I also saw as a red flag, whilst 1gw and his mates were ramping them, even at the peak. The shares crashed 80%. ONE day later, M5 sells m5 - 15 Feb 2024 - 10:22:07 - 6632 of 8843 hVIVO plc - HVO Well that's me out for now. What a journey and a few lessons learnt. Company is in fine shape and I am sure has a bright future. It seems to me that CF see more short term gain with POLB that HVO as he has said he will be buying POLB in the market. |
Posted at 30/11/2024 13:47 by sikhthetech M5,Good to see you heeded my red flags/warnings, even though you will never admit it. ;-) sikhthetech - 14 Feb 2024 - 13:49:19 - 6589 of 8843 hVIVO plc - HVO There you go, as predicted, this was repeatedly talked up. CF selling significant number, as he is now in profit. Why would he sell if there was significant growth ahead. sikhthetech - 04 Feb 2024 - 21:49:25 - 6386 of 6586 Whenever there's huge options awarded to 1 director then I see it as a red flag. A similar happened at RTHM, which I also saw as a red flag, whilst 1gw and his mates were ramping them, even at the peak. The shares crashed 80%. ONE day later, M5 sells m5 - 15 Feb 2024 - 10:22:07 - 6632 of 8843 hVIVO plc - HVO Well that's me out for now. What a journey and a few lessons learnt. Company is in fine shape and I am sure has a bright future. It seems to me that CF see more short term gain with POLB that HVO as he has said he will be buying POLB in the market. |
Posted at 20/11/2024 21:57 by sikhthetech There you go, told you these were being pumped and dumped by the blnx gang with their multiple ids.Rampers on HVO busy but Nexn quiet. Now HVO being dumped and Nexn being pumped.. Don't take my word for it, check out Nexn thread for yourselves. sikhthetech - 20 May 2024 - 13:30:47 - 7314 of 8678 hVIVO plc - HVO Chica "You need a constant flow of solid news." There was constant news and tips when they were being talked up. The Chairman dumped majority of his holding over 3 months ago. Since then hardly anything. Yet again, Nexn(ex Blnx/rthm/trmr) BB busy and HVO quiet. Check it for yourselves. The blnx pump and dump gang busy elsewhere for now with their web of lies and deceit. ;-) |
Posted at 10/9/2024 10:09 by rivaldo Good, solid H1 results - and 100% visibility over revenues for this year already.Cavendish have reiterated their 42p target price and summarise as follows: "On track to meet all targets. Once again HVO has delivered on its targets, and with CW open we are increasingly confident that targets for both near- and longer-term are achievable, which will drive compound double-digit revenue and profit growth. — HVO is strongly positioned for future growth. The company has visibility on 100% of FY 2024 revenues and, and good visibility into FY 2025. We believe EBITDA margins will be broadly flat for the next year as the company invests for future growth, revenues are expected to continue their healthy growth trajectory. As a double-digit compounder we believe that the current FY2025E EV/sales and EV/EBITDA multiples of 2.4x and 9.9x respectively are too low, and reiterate our 42p price target, which is solidly underpinned by a 10-year DCF." The most interesting part of today's note was this: "In our view this robust revenue growth will continue as HVO benefits from: — An expanding pathogen portfolio, with ten new challenge agents manufactured over the past three years. With the move to CW and the availability of an in-house BSL-3 lab and secure quarantine facilities under one roof the ability to further expand the challenge agent portfolio will increase, as shown in figure 3 below. — The global biopharma community is becoming increasingly aware of the benefit of HCTs over conventional clinical studies from the perspective of time to delivery of results, reduction in clinical trial size and cost. — Greater capacity at CW in one location compared to the previous facilities. CW offers fifty beds in one location vs forty-three beds over four locations previously, spread between QMB and three floors at the Whitechapel facility. We understand that there is the ability to further utilise the space at CW to add additional quarantine rooms if required, and that the company has the option to lease additional space on an adjacent floor, ensuring that CW is fit for purpose for a number of years. — Revenue diversification. Although HVO is first and foremost a leading HCT firm, the recent major contract win to run a 1,000 volunteer field study (the only one in the UK) as part of a multinational phase 2b influenza drug field study indicates how management is looking to leverage its expertise in associated verticals while using existing infrastructure and capabilities. In addition to field studies, clinical trial design consulting via Venn, specialist standalone lab services, standalone patient and volunteer recruitment services (leveraging the FluCamp platform) and clinical site services all offer potential revenue streams in addition to HCTs which will help to drive efficiencies by improving staff utilisation. — Being able to leverage the somewhat unique FluCamp platform to rapidly recruit appropriate volunteers when necessary. Post the Covid pandemic governments, regulatory agencies and the global biopharma industry is more aware of the threat of another global pandemic, which many experts see as “when and not if”. As seen with Covid, HVO’s leading HCT capabilities can be invaluable in shortening the time to produce an effective vaccine and/or treatment when time is of the essence. — An ongoing ability to pass on sensible price rises to customers." |
Posted at 14/8/2024 13:01 by pierre oreilly stt, If you put as much effort into researching companies as you do to trying to deramp them, then you may end up with 5 baggers like hvo for me instead of 95% losers which is your experience, and source of your silly bitterness. Get rid of emotion mate. Oopse, too late, you've lost all your money already!.How many more times are you going to post EXACTLY the same post? Directors sometimes sell shares - that's why they run companies. The return from share sales from entrepreneurs who build successful companies far exceeds their salary. It's the reward they deserve. They aren't ltbh - they have a small company skillset and interest. They sell and move onto the next one - just as cf did with small companies before hvo. It was a matched sell with Octopus who bought them, and more since. You'd be better asking yourself what Octopus saw in hvo. Do you know of Greg at Octopus? He's pretty smart imv. Within a year, I expect Octopus will bid for all hvo shares, and who can blame them. CF couldnt have sold without trashing the price and Octopus simply couldn't have bought as many without driving the price much higher, so the matched trade satisfied both parties. You have to grab opportunities while they are there. Anyhow, hvo is no longer a penny punter pi share - the price is now governed by institutions operating at this market cap level and other big investors - hence why you constant boring repetitive post has no effect on the price. Can't you see that? |
Posted at 20/7/2024 13:44 by sikhthetech Interesting post on lse by mick-b.What do you think 1gw? Or doesn't it suit your pump/dump? Snippet: "My only reservation is that big profit margins always attracts competition, sooner or later, if there isn’t a strong enough moat of IP. I’m not convinced the moat here is strong enough to prevent that happening eventually. After all, HVO built this business quite quickly in recent years, so why couldn’t someone else do the same" mick-b Posts: 23,661 Price: 30.60 No Opinion Stockopedia comments Paul Scott - HVOToday 14:00 Paul’s opinion - unchanged, I see HVO positively, so am happy to give it another GREEN LIGHT. It seems a reasonably priced, GARP share (growth at reasonable price). My only reservation is that big profit margins always attracts competition, sooner or later, if there isn’t a strong enough moat of IP. I’m not convinced the moat here is strong enough to prevent that happening eventually. After all, HVO built this business quite quickly in recent years, so why couldn’t someone else do the same, if they have the expertise and some startup funding? Hence why I think it’s not a share to chase up to expensive levels. Thankfully it’s not expensive, with a 2025 fwd PER of 18.8x, and comfort of plenty of cash sitting in the bank. So I remain positive, and let’s hope the forecasts are beaten again, which HVO has a history of doing. (SUBSCRIPTION ONLY HENCE PRINT OUT) My assertion: sikhthetech - 17 Jul 2024 - 14:43:57 - 7595 of 7639 hVIVO plc - HVO <...> Who saves the money???? Pharmas, not HVO. There's your answer as to why clients largely paid for the new facility. They spent a few million to save huge amounts. HVO make a few quid and have to carry out all the planning, recruiting and take all the risks. If there is demand then there's nothing stopping pharmas from setting up rival facilities. Why don't they? I think there's a questionable business model. |
Posted at 17/7/2024 16:29 by 1gw Well that was a good day. The cash generation from the 24% EBITDA margin on £36m of revenue obviously helped offset the likely lower cash advance position (vs year-end) due to the reduction in order book. Great performance on revenue acceleration and cash and I look forward to seeing the actual net current asset position at mid-year.On the Octopus holdings notice, perhaps worth commenting that it implies they have acquired 9m shares between 4th July (effective date of previous holdings notice) and 15th July. I think it might be reasonable to think that they were indeed the company (or one of them) that suggested to HVO that a nominal dividend would make it easier for them to invest (see post below for context). If so, then good to see the follow-through. -------------------- 1gw - 23 Sep 2023 - 09:53:51 - 4770 of 7608 hVIVO plc - HVO yump - I heard IHT funds in the presentation, so I guess it's something like Octopus. "Potential for growth and dividends The Octopus AIM Inheritance Tax Service invests in a portfolio of carefully-chosen companies listed on AIM, the world’s most successful market for fast-growing smaller companies." And in the Octopus IHT service brochure: "The 27 companies currently on the buy list for the Octopus AIM Inheritance Tax ISA share some impressive statistics: • Average turnover (forecast): £377 million. • Average profit before tax (forecast): £46.9 million. • Average dividend yield: 1.46%." If HVO can tick both boxes (growth & dividends) then it presumably makes it easier for a fund manager who's keen on the company to get it past whatever investment committee has to approve the new holding. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
